Amedisys Major Shareholder Buys $3,264,528 in Stock (AMED)
Amedisys (NASDAQ:AMED) major shareholder Kkr Asset Management Llc acquired 186,013 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, October 22nd. The stock was purchased at an average price of $17.55 per share, for a total transaction of $3,264,528.15. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
A number of research firms have recently commented on AMED. Analysts at RBC Capital downgraded shares of Amedisys from a “sector perform” rating to an “underperform” rating in a research note to investors on Monday. They now have a $9.00 price target on the stock, down previously from $10.00. Separately, analysts at TheStreet upgraded shares of Amedisys from a “sell” rating to a “hold” rating in a research note to investors on Wednesday, October 2nd. Finally, analysts at Deutsche Bank raised their price target on shares of Amedisys from $9.00 to $11.00 in a research note to investors on Friday, August 2nd. They now have a “hold” rating on the stock. Four investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. Amedisys has a consensus rating of “Hold” and an average target price of $10.00.
Shares of Amedisys (NASDAQ:AMED) traded down 1.48% on Wednesday, hitting $17.28. The stock had a trading volume of 198,968 shares. Amedisys has a 52-week low of $8.81 and a 52-week high of $18.70. The stock has a 50-day moving average of $15.95 and a 200-day moving average of $12.5. The company’s market cap is $556.1 million.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.06 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.10 by $0.04. The company had revenue of $313.10 million for the quarter, compared to the consensus estimate of $328.02 million. During the same quarter last year, the company posted $0.27 earnings per share. Amedisys’s revenue was down 13.8% compared to the same quarter last year. Analysts expect that Amedisys will post $0.56 EPS for the current fiscal year.
Amedisys, Inc (NASDAQ:AMED) is a health care company focused on bringing home the continuum of care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.